“…TXNIP is also overexpressed in the context of diabetes. Data from the literature identify TXNIP as a potential target in diabetes complications such as diabetic retinopathy, nephropathy, cardiomyopathy, and impaired post-ischemic revascularization [ 59 , 67 , 79 , 154 , 155 , 156 , 157 , 158 , 159 , 160 , 161 , 162 , 163 , 164 , 165 , 166 , 167 , 168 , 169 , 170 , 171 , 172 , 173 , 174 , 175 , 176 ]. In a rat model of diabetic cardiomyopathy, TXNIP deletion in cardiomyocytes induces an improved inotropic response to β-adrenergic stimulation [ 144 ].…”